Melanoma patients diagnosed at a younger age tend to have a higher frequency of CDKN2A somatic alterations, however, with 72% of patients aged 30 years or younger displaying melanoma-associated CDKN2A alterations, and this diminishes with increasing age. This evidence concerns the gene CDKN2A and melanoma.